BofA analyst Tazeen Ahmad raised the firm’s price target on Incyte (INCY) to $87 from $86 and keeps a Buy rating on the shares. The firm updated models in smid-cap biotech as part of a Q1 earnings preview.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte price target lowered to $61 from $69 at UBS
- Knight Therapeutics announces launch of Minjuvi in Mexico
- Incyte price target lowered to $65 from $69 at Morgan Stanley
- Incyte’s Hold Rating: Balancing Pipeline Challenges and Established Product Valuation
- Monday.com, Incyte, Lucid, Bloom, EQT: Trending by Analysts